BioMarin’s Naglazyme For Maroteaux-Lamy Syndrome To Debut By End Of June
This article was originally published in The Pink Sheet Daily
Executive Summary
Sixty-rep, in-house sales force will market the enzyme replacement therapy, which received orphan approval from FDA. Postmarketing commitments include evaluation of Naglazyme’s impact on skeletal dysplasia in infants and a clinical surveillance program.